<SEC-DOCUMENT>0001628280-25-048931-index.html : 20251104
<SEC-HEADER>0001628280-25-048931.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104164841
ACCESSION NUMBER:		0001628280-25-048931
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Werewolf Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001785530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				823523180
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251450256

	BUSINESS ADDRESS:	
		STREET 1:		200 TALCOTT AVENUE
		STREET 2:		2ND FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-952-0555

	MAIL ADDRESS:	
		STREET 1:		200 TALCOTT AVENUE
		STREET 2:		2ND FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UBS Oncology Impact Fund L.P.
		CENTRAL INDEX KEY:			0001691428
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		399 BOYLSTON STREET
		STREET 2:		SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-425-9200

	MAIL ADDRESS:	
		STREET 1:		399 BOYLSTON STREET
		STREET 2:		SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
Document 1 - file: primary_doc.html

Document 1 - RAW XML: primary_doc.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>table_iix20251104.pdf
<DESCRIPTION>EX-99
<TEXT>
Document 2 - file: table_iix20251104.pdf

</DOCUMENT>
</SEC-DOCUMENT>